Vaxcyte’s stock up after pneumococcal vaccine proves non-inferiority
Vaxcyte’s stock has skyrocketed as its invasive pneumococcal disease (IPD) and pneumococcal pneumonia vaccine has met its endpoints in a…
News
EADV26: Key late-stage readouts from the conference
Surrozen secures FDA clearance for SZN-8141 clinical trial
Genmab reports Phase I/II data for Rina-S in ovarian cancer
Brainomix’s e-Lung shows progression and treatment response in Phase III trial
EASD 2026: Regeneron’s muscle preserver shows benefit at lower doses
Zealand dips on Boehringer-paired obesity drug’s Phase III result
Cyclo goes forth with Niemann-Pick drug’s approval bid despite Phase III miss
